Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care.

Helsper CW, Van Vliet LM, Velthuizen ME, de Wit NJ, Beijaert RP, Butter E, van Gent-Wagemakers MP, Witteveen EO, Zweemer RP, van Dulmen SM, Ausems MG.

Br J Gen Pract. 2018 Nov;68(676):e750-e756. doi: 10.3399/bjgp18X699533.


Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.

Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, Voest EE.

Neoplasia. 2010 Jan;12(1):87-94.


Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.

Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH.

Clin Cancer Res. 2008 Nov 15;14(22):7535-44. doi: 10.1158/1078-0432.CCR-08-0438.


Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81.


A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH.

Clin Cancer Res. 2007 Jun 1;13(11):3276-85.


Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE.

J Clin Oncol. 2006 Apr 1;24(10):1491-8.


Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.

Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE.

Clin Cancer Res. 2003 Sep 15;9(11):4025-33.


Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid.

Verdonck LF, Witteveen EO, van Heugten HG, Rozemuller E, Rijksen G.

Cancer Res. 1990 Jul 1;50(13):4020-5.


Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.

Witteveen EO, Verdonck LF, Nieuwenhuis HK, Dekker AW.

Haematol Blood Transfus. 1990;33:309-13. No abstract available.


Supplemental Content

Loading ...
Support Center